HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $510 Price Target
Alnylam Pharmaceuticals, Inc +1.92% Post
Alnylam Pharmaceuticals, Inc ALNY | 339.41 339.41 | +1.92% 0.00% Post |
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:
ALNY) with a Buy and maintains $510 price target.
